Journal of Pharmacy and Pharmacology · 2008 · 52 citations · 16 references
Life SciencesBiochemistryPharmacologyExperimental PharmacologyLipid BiochemistryRodent MedicineCholesterol MetabolismLipid DisordersLipid MetabolismLipid-lowering TherapyLiver DiseaseSterol MetabolismCholesterol-lowering EffectsHepatic Lipid AccumulationHepatic Lipid MetabolismHepatic Lipid StorageHepatic Sterol MetabolismLipid Metabolism Effects
The effects of schisandrin B (Sch B) on liver and serum lipid contents were investigated in mice with experimentally-induced hypercholesterolaemia. Hypercholesterolaemia was induced either by oral administration of a cholesterol/bile salts mixture (2/0.5 g kg(-1)) for four days or by feeding a high fat/cholesterol/bile salts (10/1/0.3%, w/w) diet for seven days. Daily co-administration of Sch B (50-200 mg kg(-1), i.g.) for four or six days, respectively, decreased hepatic total cholesterol (TC) and triglyceride (TG) levels (by up to 50% and 52%, respectively) in hypercholesterolaemic mice. Sch B treatment also increased hepatic indices (14-84%) in hypercholesterolaemic mice. The results indicated that Sch B treatment could decrease hepatic TC and TG levels, and increase liver weight, in mouse models of hypercholesterolaemia. Fenofibrate treatment (100 mg kg(-1)) produced effects similar to those of Sch B on the hepatic index and lipid levels of hypercholesterolaemic mice.
16
Fatty liver and the metabolic syndrome among Shanghai adults
Jian-Gao Fan, JUNE ZHU, Xingjian Li et al. · Journal of Gastroenterology and Hepatology · 2005 · 187 citations
Yutaka Miura, Mayu Hosono, Chiaki Oyamada et al. · British Journal Of Nutrition · 2005 · 85 citations · Full text